The Amiodarone Derivative KB 130015 [ 2-Methyl-3-( 3 , 5-diiodo-4-carboxymethoxybenzyl ) benzofuran ] Induces an Na-Dependent Increase of [ Ca 2 ] in Ventricular Myocytes
V. Bito,D. Dauwe,F. Verdonck,K. Mubagwa,K. Sipido
Abstract:KB130015 [KB; 2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran] is a novel amiodarone derivative designed to retain the antiarrhythmic effects without the side effects. Unlike amiodarone, KB slows Na current inactivation and could, via an increase in [Na ]i, potentially lead to Ca 2 overload. Therefore, we studied the effects of KB on Na and Ca handling in single pig ventricular myocytes using the whole-cell ruptured patch-clamp technique and K5fluo-3 as [Ca 2 ]i indicator. KB at 10 M did not prolong action potential duration but slightly increased the early plateau; spontaneous afterdepolarizations were not observed. The amplitude of the [Ca ]i transient was larger (434.9 37.2 versus 326.8 39.8 nM at baseline, n 13, P 0.05), and the time to peak [Ca ]i was prolonged. During voltage-clamp pulses, [Ca ]i transient peak was also larger (578.1 98.9 versus 346.4 52.6 nM at baseline, P 0.05). Although L-type Ca current was reduced (by 21.9% at 10 mV, n 9, P 0.05), sarcoplasmic reticulum Ca content was significantly enhanced with KB. Forward Na /Ca exchange was significantly decreased after KB application, but reverse mode of the Na /Ca exchanger was significantly larger, suggesting an increase in [Na ]i with KB. This was confirmed by a 2-fold increase of the [Na ]-dependent current generated by the Na/K-ATPase (from 0.17 0.02 to 0.38 0.06 pA/pF, P 0.05). In conclusion, as predicted from the slowing of INa inactivation, KB130015 leads to an increase in [Na ]i and consequently in cellular Ca 2 load. This effect is partially offset by a decrease in ICaL resulting in a mild inotropic effect without the signs of Ca overload and related arrhythmias usually associated with Na channel openers. Sudden cardiac death, mostly related to arrhythmias, is a major cause of mortality (Zipes and Wellens, 1998; Richter et al., 2005). Lethal arrhythmias occur in a many cardiac diseases, including congenital ion channel mutations without structural heart disease as well as genetic and acquired cardiomyopathies. Particularly in the setting of ischemic cardiomyopathy and heart failure, mortality due to ventricular arrhythmias is high, and the search for efficient antiarrhythmic drugs has been frustrating. The recent introduction of device therapy with an implantable cardiac defibrillator (ICD) has been a major success in improving survival. It was superior to any medical therapy (AVID Investigators, 1997; Bokhari et al., 2004). However, cost considerations and the impact on quality of life make it an option that is not always available (Epstein, 2004; Josephson and Wellens, 2004). Efficient and safe drugs for treatment of ventricular arrhythmias are still needed. In addition, association of pharmacotherapy with the ICD can substantially reduce the number of electroshocks, thus improving efficiency of treatment and quality of life. The major drawback of current antiarrhythmics is the earlier experiences of increased mortality in the CAST studies (CAST Investigators, 1989). The newer class III agents with a pure K channel blocking action have also been associated with proarrhythmia, notably a high incidence of Torsade-de-Pointes in the SWORD study (Waldo et al., 1996). They are not a first choice for ventricular arrhythmias occurring in the setting of ischemic cardiomyopathy where there is often already prolongation of the action potential at baseline. The multiaction drug amiodarone has not been reported to have the proarrhythmic effect of other class III agents (Amiodarone Trials Meta-Analysis Investigators, 1997). It has specific effects on multiple carThis work was supported by grants from the FWO, the Flanders Fund for Scientific Research (to K.R.S. and K.M.). Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.105.092221. ABBREVIATIONS: ICD, implantable cardiac defibrillator; KB130015 (KB), 2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran; DHO, dihydroouabain; SR, sarcoplasmic reticulum; CTRL, control; DPI 201-106, ( )-4-[3-(4-diphenylmethyl-1-piperazinyl)-2-hydroxy propoxy]-1Hindole-2-carbonitrile; BDF 9148, ( )-4-[3-[[1-(diphenylmethyl)-3-azetidinyl]oxy]-2-hydroxypropoxy]-1H-indole-2-carbonitrile; EAD, early afterdepolarization. 0022-3565/06/3161-162–168$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 316, No. 1 Copyright © 2006 by The American Society for Pharmacology and Experimental Therapeutics 92221/3065710 JPET 316:162–168, 2006 Printed in U.S.A. 162 at A PE T Jornals on July 5, 2017 jpet.asjournals.org D ow nladed from diac ion channels that differ in acute and chronic treatment (Kodama et al., 1997). After myocardial infarction, treatment with amiodarone has been reported to prevent arrhythmic death (Cairns et al., 1997; Julian et al., 1997), but a recent trial in heart failure patients confirmed superiority of ICD (Bardy et al., 2005). Because of its low proarrhythmic potential, amiodarone remains a widely used and efficient drug. However, its long-term clinical use is limited by its significant extracardiac toxicity. Because of close structural similarity with thyroid hormones, symptoms of hypothyroidism can occur. Corneal deposits and development of lung fibrosis can be major reasons for discontinuation of amiodarone treatment (Martin, 1990). Therefore, several compounds have been developed based on the amiodarone structure, aiming to retain the efficiency and cardiac safety of amiodarone, with less of the extra-cardiac side effects. KB130015 (KB) is one such new drug (Carlsson et al., 2002). Preliminary data in guinea pig suggest that KB has a toxicity profile more advantageous that amiodarone. In the same study in guinea pig papillary muscle, KB has been shown to prolong action potential duration suggesting a potential antiarrhythmic effect. Like amiodarone, it acts on many ion channels, including Ca , Na , and K channels (for review, see Mubagwa et al., 2003). Unlike amiodarone, KB slows the inactivation of voltage-dependent Na channels (Macianskiene et al., 2003b). This effect is expected to increase intracellular [Na ] and thus the cellular Ca load through an increased influx via Na /Ca exchange, a potentially positive inotropic effect. However, KB also decreases L-type Ca current, which would lower the cellular Ca load (Macianskiene et al., 2003a). The net effect of these opposite actions is yet unknown and is of considerable interest given the earlier experience of increased mortality during chronic treatment in patients with heart failure with agents that increased cellular Ca (Packer, 1993). Preliminary data indicated that KB increased cell shortening, especially at high concentrations (Mubagwa et al., 2003). Therefore, in the present study, we examined the effect of KB on cellular Ca load and Na /Ca exchange function associated with alterations in increased Na influx. We used pig ventricular myocytes that have action potential duration and frequency behavior close to that of humans. Materials and Methods Cell Isolation. Single left ventricular myocytes were enzymatically isolated from the hearts of domestic pigs of either sex (body weight, 41 4 kg; n 10) as previously described (Stankovicova et al., 2000). We used only cells isolated from the midmyocardial layer, mostly from the left ventricular anterior free wall, but in a number of experiments also from the left ventricular posterior wall. Cells were stored at room temperature and used within 24 h. Solutions and Drugs. All experiments were performed in normal Tyrode’s solution 137 mM NaCl, 5.4 mM KCl, 0.5 mM MgCl2, 1.8 mM CaCl2, 11.8 mM Na-Hepes, and 10 mM glucose 10, pH 7.40. The pipette solution for whole-cell patch clamp contained 120 mM Kaspartate, 10 mM NaCl, 20 mM KCl, 10 mM K-Hepes, 5 mM MgATP, and 0.05 mM K5fluo-3, pH 7.2. A stock solution of KB130015 (a gift from Karo-Bio, Huddinge, Sweden) was prepared in dimethyl sulfoxide at a concentration of 10 mM. The final concentration to be used was obtained by diluting 1:1000 (v/v) in normal Tyrode’s solution. A 1:1000 dilution of the solvent in normal Tyrode’s solution had no effects by itself (ncells 9, data not shown). NiCl2 (Sigma-Aldrich, St. Louis, MO) was dissolved directly in the Tyrode’s solution at 2.5 mM. Dihydroouabain (DHO; Sigma-Aldrich) was prepared as a 1 mM stock in distilled water and diluted 1:100 in the Tyrode’s solution before use. Experimental Setup. [Ca ]i transients were measured with fluo-3 as a [Ca ]i indicator. The setup for fluorescence and membrane currents recording was as described before (Antoons et al., 2002). The fluorescence signals were corrected for the background recorded after the seal formation. This signal was further calibrated to [Ca ]i values, using an Fmax reading obtained at the end of the experiment (Trafford et al., 1999; Antoons et al., 2002). Experimental Protocols. We recorded action potentials and [Ca ]i transients in current clamp mode, applying 5-ms current injections to trigger action potentials. During voltage-clamp experiments, the holding potential was 70 mV. For measuring L-type Ca current, ICaL, the Na current was inactivated by a prepulse to 50 mV. ICaL was taken as the difference between the peak inward current and the current at the end of the pulse during depolarizations to 40 up to 50 mV. The Ca content of the sarcoplasmic reticulum (SR) was measured during a fast application of 10 mM caffeine at a holding potential of 50 mV following a train of 10 conditioning pulses from 70 to 10 mV at 1 Hz. The amplitude of the reverse mode of Na /Ca exchange current was measured as the nickel-sensitive current during a depolarizing step to 40 mV. The current generated by the Na/K-ATPase was measured as DHO-sensitive current at a holding potential of 50 mV following a train of 10 conditioning pulses from 70 to 10 mV at 1 Hz. All the experiments were done at 37°C. Statistics. All data are shown as mean S.E.M. As statistical test, a paired Student’s t test wa